Richard is Chief Financial Officer of Averna Therapeutics, bringing more than 25 years of biopharmaceutical finance and operational leadership experience. Most recently, he served as CFO of CARISMA Therapeutics, where he oversaw financial strategy and operations for the clinical-stage company. Prior to CARISMA, he was CFO at Passage Bio, where he helped guide the company’s evolution from a private startup to a publicly traded biotechnology company. Earlier in his career, he served as Executive Vice President and CFO at Context Therapeutics, CFO at Vitae Pharmaceuticals through its acquisition by Allergan, and held senior finance roles at ViroPharma through its acquisition by Shire.
He holds a B.S. in Accounting from Saint Joseph’s University and was previously licensed as a Certified Public Accountant.
Our Team
